Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

Biotechnology • Healthcare • San Francisco, CA, United States • VIR (NMS)

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

415 906 4324 1800 Owens Street, San Francisco, CA 94158, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

H.C. Wainwright reiterates Buy rating on Vir Biotechnology stock By Investing.com - Investing.com Nigeria
Investing.com Nigeria • Dec 30
Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.4% - Here's What Happened - MarketBeat
MarketBeat • Dec 30
With 59% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing - Yahoo Finance
Yahoo Finance • Oct 28
New hepatitis delta therapy advances as partners share trial costs - Stock Titan
Stock Titan • Dec 16
Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks - Genetic Engineering and Biotechnology News
Genetic Engineering and Biotechnology News • Jul 31

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Vir Biotechnology, Inc. had layoffs?
No layoff events have been recorded for Vir Biotechnology, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Vir Biotechnology, Inc. have?
Vir Biotechnology, Inc. has approximately 408 employees.
What industry is Vir Biotechnology, Inc. in?
Vir Biotechnology, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Vir Biotechnology, Inc. a publicly traded company?
Yes, Vir Biotechnology, Inc. is publicly traded under the ticker symbol VIR on the NMS. The company has a market capitalization of approximately $0.83 billion.
Where is Vir Biotechnology, Inc. headquartered?
Vir Biotechnology, Inc. is headquartered in San Francisco, CA, United States at 1800 Owens Street, San Francisco, CA 94158, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.